Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Antares: Approval of Xyosted is a Matter of When, Not If (ATRS, $2.12, Buy)

The Issue

Antares received a complete response letter for Xyosted that did not cite any questions relating to efficacy, manufacturing, quality…
Read more…